JPMorgan lowered the firm’s price target on MetLife to $81 from $82 and keeps an Overweight rating on the shares. The analyst’s long-term fundamental outlook for the life insurance business remains cautious, but the firm are bullish on stocks. The positive stance reflects the tailwind from favorable macro conditions, healthy balance sheets, and negative investor sentiment, the analyst tells investors in a research note. JPMorgan views easing concerns about commercial real estate as a key positive catalyst and considers potential deterioration in corporate credit a “major downside risk” for life stocks.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MET:
- MetLife price target raised to $78 from $73 at Piper Sandler
- MetLife CFO says ‘quality will win out in every class of real estate’
- 5 Top Financial Stocks to Buy Now, According to Analysts – November 2023
- Airbnb downgraded, Expedia upgraded: Wall Street’s top analyst calls
- MetLife reinstated with an Overweight at Barclays